KRAS and acute myeloid leukemia: When the analyses were restricted to pediatric AML patients with 11q23/KMT2A rearrangements (Table 3), KRAS mutation was a significant poor prognostic factor for EFS and OS with an HR for EFS of 2.10 (p = 0.05) and OS of 2.39 (p = 0.054).